Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer.
François BertucciAlexandre De NonnevillePascal FinettiEmilie MamessierPublished in: Cancer communications (London, England) (2023)